Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Orexigen Therapeutics Inc (NASDAQ:OREX)

1.78
Delayed Data
As of Oct 20
 -0.04 / -2.20%
Today’s Change
1.65
Today|||52-Week Range
5.70
+2.30%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$27.5M

Company Description

Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities includes recruiting personnel, conducting research and development, including clinical trials, raising capital and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

Contact Information

Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
La Jolla California 92037
P:(858) 875-8600
Investor Relations:

Employees

Shareholders

Mutual fund holders3.12%
Other institutional27.49%
Individual stakeholders0.14%

Top Executives

Michael A. NarachiPresident, Chief Executive Officer & Director
Thomas R. CannellChief Operating Officer & Executive Vice President
Jason KeyesChief Financial Officer & Senior Vice President
Thomas P. LynchSecretary, Chief Administrative Officer & EVP
Peter D. FlynnSVP, Head-Development, Regulatory Affairs & Safety